C
Cumberland Valley Retina Consultants (CVRC) | Hagerstown, MD
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Ranibizumab
EYE103
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
2 of 3 total trials
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...
Enrolling
Diabetic Macular Edema (DME)
Drug: EYE103
Drug: Ranibizumab
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...
Enrolling
Wet Age-related Macular Degeneration
Wet AMD
Genetic: RGX-314
Biological: Ranibizumab (LUCENTIS®)
Trial sponsors
E
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems